BICO Group AB (publ) announces an increase in number of shares and votes
The number of shares and votes in BICO Group AB (publ) have increased as a result of a directed issue of 4,250,000 shares of series B which was carried out as part of the financing for the acquisition of QInstruments GmbH. The Board of Directors has on October 7, 2021, based on the authorization granted by the Annual General Meeting held on April 26, 2021, resolved on the directed issue of shares.
Furthermore, the number of shares and votes in BICO Group AB (publ) have increased as a result of a directed issue of 172,852 shares of series B which also was carried out as part of the financing for the acquisition of QInstruments GmbH. The Board of Directors has on October 25, 2021, based on the authorization granted by the Annual General Meeting held on April 26, 2021, resolved on the issue in kind.
Through the above-mentioned events, which the Swedish Companies Registration Office registered during October, the number of shares and votes in BICO Group AB (publ) increased by a total of 4,422,852.
As of October 29, 2021, the total number of registered and outstanding shares of BICO Group AB (publ) amounts to 62,130,269, whereof 1,500,000 are shares of series A, together carrying in total 15,000,000 votes, and 60,630,269 are shares of series B, together carrying in total 60,630,269 votes. The share capital amounts to SEK 1,553,256.725000. The company does not hold any treasury shares.
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
Email: il@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on October 29, 2021 at 08:00 (CEST).
About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com